MK-677
Ibutamoren
MK-677 (Ibutamoren) is an orally active growth-hormone secretagogue — a non-peptide molecule that raises growth hormone and IGF-1 with a single daily capsule, no injections required. That convenience, plus a long half-life and durable effect, is why it's one of the most popular compounds in the GH-support world. This guide covers how MK-677 works, what the research shows, dosing references, its real side effects, and legal status.
MK-677 quick facts
| Reported research dosing | 10mg-25mg |
| Route | Oral |
| Cycle length | 3-6 Months |
| Frequency | 1x Daily Anytime |
| Half-life | ~24 hrs |
| Forms | Oral |
| Evidence level | Human trials |
Oral convenience, but it drives appetite and water — respect that. Not for everyone.
How MK-677 works
MK-677 is an oral ghrelin-receptor (GHSR-1a) agonist — it mimics the hunger hormone ghrelin to stimulate a pulsatile release of growth hormone and sustain elevated IGF-1 for up to 24 hours. Like the injectable secretagogues, it works with your own axis: GH release still responds to GHRH and somatostatin, so it raises the baseline without shutting your system down the way exogenous HGH does. Its big practical advantage is being oral and long-acting — one daily dose vs multiple injections.
What the research shows
Across human studies, MK-677 has reliably raised GH and IGF-1 without meaningfully raising cortisol. The standout is the Nass et al. 2-year trial, which showed MK-677 maintained its GH-elevating effect over extended use without tolerance — an important finding, since many GH-boosting approaches fade. Research interest spans body composition, bone density, sleep quality and recovery. Note: despite this, MK-677 failed to gain approval for its originally-studied indications, so it remains a research compound.
MK-677 dosing (research reference)
Because of its ~24-hour half-life, the literature references a single daily oral dose as sufficient to keep GH and IGF-1 elevated — a key contrast with short-acting injectable secretagogues that need multiple daily shots. It's oral, so there's no reconstitution involved. This summarizes existing references for education only and is not dosing advice or a recommendation for human use.
Side effects — the honest picture
MK-677 has a few characteristic effects worth knowing. Because it activates the ghrelin receptor, it increases appetite — often the first sign it's 'working,' but a real consideration if you're in a cut. It commonly causes fluid retention, especially in the first 4–6 weeks. And most importantly, it can raise fasting blood sugar and insulin and cause mild insulin resistance in some people — so blood-sugar monitoring is genuinely important, particularly for anyone with metabolic risk factors.
Related compounds & comparisons
MK-677 targets the same GH axis as the injectable secretagogues but from a different angle. Ipamorelin and other GHRPs give sharper, shorter pulses via injection and don't raise appetite the way MK-677 does; CJC-1295 is a GHRH often stacked with those. MK-677's trade-off is oral convenience and a sustained IGF-1 elevation vs more appetite, fluid retention and blood-sugar considerations.
Legal & regulatory status
MK-677 is not FDA-approved for any indication and is sold as a research compound (research use only). It is also banned in competitive sport under WADA. Its status, like other GH-axis compounds, is subject to ongoing regulatory attention. Follow the laws and sport rules that apply to you.
✅ Clinically validated
- Real human trials, and they are the reason to be careful rather than excited. A two-year randomised trial in healthy older adults raised IGF-1 to young-adult levels and increased fat-free mass by roughly 1.6 kg — the efficacy signal is not in doubt. The same programme showed increased fasting glucose and reduced insulin sensitivity.
- Development for frailty was discontinued and a hip-fracture trial stopped early. That is a different kind of failure from a compound that does nothing — it worked, and the metabolic cost was judged not worth it for a frail elderly population on a long-term daily drug. Someone using it in short courses with normal glucose handling is not that population, which is the honest read and also not a licence to ignore the finding.
📊 Correlative data
- Very widely used, and the reported experience matches the trials closely: marked appetite increase, water retention and improved sleep depth within days, lethargy and puffiness in a substantial minority.
- Because it is orally active and long-acting, people run it for months, which is precisely the pattern the glucose data argues against.
🧪 Theoretical / extrapolated
- An orally-bioavailable ghrelin-receptor agonist with a ~24-hour half-life. Continuous receptor occupancy is the key mechanistic difference from injectable secretagogues — it produces a sustained elevation rather than a pulse, and sustained GH/IGF-1 signalling is what predicts the insulin resistance the trials found.
- The same continuous ghrelin signalling predicts the appetite effect, which is a feature if you are trying to gain and a serious problem if you are not.
These tiers tell you how much human evidence exists — not how well something works. This is the research space, and most of what’s in here is new rather than disproven. Something sitting at “theoretical” usually means nobody has funded the trial, not that the trial was run and failed.
The trap runs the other way too: something can be clinically validated and still do very little for you specifically. A statistically significant result in a study population is not a promise about your body.
- ✅ Clinically validated — human randomised trials or meta-analyses support it. The strongest footing available.
- 📊 Correlative — observational or epidemiological data. Suggestive, and genuinely useful for direction, but it cannot establish cause.
- 🧪 Theoretical / mechanistic — the mechanism is understood and often demonstrated in cells or animals, and the human trial doesn’t exist yet. Unproven is not the same as ineffective. Plenty of what’s standard practice today sat here five years ago.
✗ is a safety flag, not a grade. Where you see it, the concern is harm — not a disappointing trial. A compound tested for one purpose and found not to help there can still be worth studying somewhere else, so a negative result never gets rendered as a cross. It sits alongside the tier, because something can be both well-studied and genuinely risky.
My job is to tell you which one you’re looking at, and let you make the call. Grading something low isn’t me dismissing it — it’s me refusing to oversell it. This is the research space, and being able to reason forward from a mechanism matters as much as waiting for the trial.
MK-677 — safety, predicted from mechanism
Much of this compound class has never been through a human safety trial. Rather than say nothing — or print a generic warning — this is what its known mechanism predicts could go wrong, and what you can do about it. Predictions are labelled as predictions.
What the mechanism predicts
Derived from what this molecule does, not from a trial.
- Everything here follows from one fact: these raise GH and therefore IGF-1. The predicted problems are the known consequences of elevated GH/IGF-1, drawn from acromegaly and clinical GH therapy where it HAS been studied — insulin resistance and rising fasting glucose, fluid retention (puffy hands and face, and the ring that stops fitting), carpal tunnel symptoms from that same fluid pressing on the median nerve, and joint aches.
- The proliferation question is the serious one. IGF-1 is a growth signal, and growth signals do not distinguish between tissue you want to grow and tissue you do not. There is no evidence these compounds cause cancer. There is also a clear mechanistic reason not to run them with an active or recent malignancy, and that reasoning does not require a trial to be sound.
What has actually been reported
- Injection-site reactions, transient flushing, tingling and head-rush on dosing — most commonly with the GHRPs, which also release cortisol and prolactin at higher doses.
- Increased hunger is near-universal with the ghrelin-mimetic ones (GHRP-6, MK-677, Hexarelin). That is the mechanism working, not a side effect — the same receptor drives GH release and appetite.
How to reduce the risk
Each of these follows from the same mechanism as the prediction.
- Draw an IGF-1 baseline BEFORE you start. Once you are on, that number is the drug and you have permanently lost the comparison. This is the single highest-value thing on this list and it costs one blood draw.
- Watch fasting glucose and HbA1c, not the scale. Insulin resistance is the most likely thing to move and the one you cannot feel. Re-test at 8–12 weeks. If fasting glucose is climbing, that is your signal to cut the dose or come off — long before anything shows up symptomatically.
- Dose at night, on an empty stomach. GH release is pulsatile and largest during early sleep; food, and carbohydrate in particular, blunts the pulse through insulin. This is not a ritual — it is the same mechanism working with you rather than against you.
- Don't run a secretagogue through a high-carbohydrate surplus. The predicted problem is insulin resistance; adding a large carb load is pushing the same lever from the other end.
- Cycle rather than run continuously. Most of the predicted problems — fluid retention, carpal tunnel, glucose drift — are dose-and-duration dependent and reverse on cessation. Time off is the cheapest safety intervention available.
- If fluid retention is the issue, it usually resolves on a dose reduction long before it needs anything else. Reach for the dose before you reach for a diuretic.
What it does to your bloodwork
A fact about the assay, not a guess about the drug.
- IGF-1 drawn on-cycle is not your baseline — it is the drug working, and it will read high. If you want a real baseline, draw before starting or after a proper washout.
- Watch fasting glucose and HbA1c, because insulin resistance is the most likely thing to move and the one you will not feel.
- GHRP-6 and Hexarelin can raise prolactin and cortisol; if you are chasing an unexplained prolactin result, this is a candidate.
What it overlaps with
- Stacking two secretagogues that work by the same route is redundancy, not synergy. A GHRH analogue (CJC-1295, Sermorelin, Tesamorelin) plus a ghrelin mimetic (Ipamorelin, GHRP-2, GHRP-6) is the deliberate pairing — two different levers on the same axis. Two GHRH analogues together is paying twice for one lever.
Don't run this if
- Active or recent malignancy — the IGF-1 reasoning above.
- Diabetes or poor glycaemic control, unless you are monitoring fasting glucose and HbA1c and know what you are looking at.
- Untreated diabetic retinopathy.
The honest unknown
- Nobody has run long-term studies of intermittent secretagogue use in healthy adults. The specific unmeasured thing is what years of repeatedly pushing IGF-1 above your natural set point does — not whether a single cycle is tolerable, which it evidently is.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Fasted — and pre-bed is the best of the windows
Food is the problem here, and specifically carbohydrate and fat. Both trigger somatostatin release, and somatostatin is the brake on growth hormone — eating before the injection pharmacologically cancels it. Two clear hours either side.
Pre-bed is the strongest window because the largest natural GH pulse happens in the first hours of deep sleep, so you are stacking with it rather than asking the pituitary for something it is not primed for. Fasted pre-training is the second-best, for the same reason in a different rhythm.
Derived from half-life, route and mechanism — not from a dosing trial. Reasoned, and labelled as reasoned.
Where to get MK-677
Buy MK-677 at Disguised Alpha →MK-677 — interference & stacking
Predicted from mechanism, not from an interaction study. There are no trials of these combinations — what follows is what the biology implies, so treat it as a reason to watch something, not as a finding.
What MK-677 moves on your bloodwork
These are the markers this compound is expected to move, and which direction. Knowing that in advance is mostly about NOT panicking: some of these moving is the compound working.
- IGF-1 (Insulin-like Growth Factor 1) — ↑ expected to rise
This is the point. IGF-1 rising is the compound doing its job — it is the stable downstream readout of a GH pulse.
What to do: Test it before you start and again at 6–8 weeks. It is the only number that tells you whether the product was real and the dose was enough. - Growth Hormone, Serum — ✕ unreliable here
A random GH level is close to meaningless here. GH is secreted in pulses during deep sleep and sits undetectable between them, so a daytime draw catches a trough almost every time — including when the compound is working perfectly.
What to do: Do not use GH to judge a secretagogue. Read IGF-1 instead. - Fasting Insulin — ↑ expected to rise
GH is a counter-regulatory hormone: it opposes insulin. Fasting insulin and glucose drifting up is the predicted trade-off, not a surprise.
What to do: Check fasting insulin and HbA1c at baseline and again at 8–12 weeks. This is the marker that decides whether you keep running it. - HbA1c (Hemoglobin A1c) — ↑ expected to rise
Same mechanism, longer window — a slow drift rather than a jump.
What to do: Pair it with fasting insulin; either alone can mislead. - Free T4 (Thyroxine) — ↓ expected to fall
GH accelerates the peripheral conversion of T4 to T3, so free T4 can fall while free T3 holds or rises. Read alone it looks like new hypothyroidism, and it usually isn't.
What to do: Run a full thyroid panel rather than TSH alone before concluding anything.
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Get the complete breakdown for MK-677 — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →Everything above follows from one fact: these raise GH and therefore IGF-1. Nothing here needs a trial of the specific molecule.
Bloodwork to run alongside MK-677
Run these before you start, and again after 8–12 weeks. A baseline you didn’t take is one you can never go back for.
| Marker | What it’s watching for |
|---|---|
| Fasting Insulin | MK-677 worsens insulin sensitivity. This is the trade, not a rumour |
| HbA1c (Hemoglobin A1c) | The three-month confirmation of that trade |
| IGF-1 (Insulin-like Growth Factor 1) | What you're dosing against |
| Comprehensive Metabolic Panel (CMP) | Fasting glucose, liver and kidney |
| Complete Blood Count (CBC) with Differential | Baseline before a compound usually run for months |
The Running GH Peptides or MK-677 panel covers these in one order — 9 markers, $132.30 with the discount applied.
Check results you already have → · All 102 markers A–Z
MK-677 — frequently asked questions
What is MK-677 (Ibutamoren)?
MK-677 is an orally active, non-peptide growth-hormone secretagogue that mimics ghrelin to raise growth hormone and IGF-1 with a single daily capsule — no injections needed.
How does MK-677 work?
It binds the ghrelin receptor (GHSR-1a) to stimulate pulsatile GH release and sustain elevated IGF-1 for up to 24 hours, while preserving your own GH feedback axis rather than replacing it like injected HGH.
Does MK-677 build tolerance?
The 2-year Nass et al. trial found MK-677 maintained its GH-elevating effect over extended use without tolerance — a notable finding versus GH approaches that fade over time.
How is MK-677 dosed?
Its ~24-hour half-life means the literature references a single daily oral dose to keep GH and IGF-1 elevated. It's oral, so no reconstitution is needed. This is educational, not dosing advice.
What are the side effects of MK-677?
Most commonly increased appetite and fluid retention (especially the first 4–6 weeks), and — importantly — it can raise fasting blood sugar and insulin and cause mild insulin resistance in some people, so blood-sugar monitoring matters.
MK-677 vs ipamorelin — what's the difference?
MK-677 is oral, long-acting and raises appetite/IGF-1 for ~24 hours; ipamorelin is an injectable that gives sharper, cleaner GH pulses without much appetite change. Different trade-offs, same GH axis.
Is MK-677 FDA-approved?
No. MK-677 is not FDA-approved for any indication and is sold as a research compound. It's also banned in competitive sport under WADA.
References & further reading
- MK-677 (Ibutamoren) research guide — clinical mechanisms (Loti Labs)
- MK-677 (Ibutamoren): mechanism and the GH/IGF-1 axis
- MK-677 (Ibutamoren): IGF-1 effects, appetite & blood-sugar considerations
Want Coach Cam's exact MK-677 protocol?
Dosing schedules, stacking, cycle timing and my personal notes live inside the Academy — plus the full interactive Vault of 237 compounds & 350 supplements.
Join the Academy — $10/mo →What MK-677 is used for
MK-677 appears under 3 goals in the Vault’s goal router, grouped by the mechanism it works through rather than by how much trial evidence exists. Each link opens that pathway in full, with the alternatives beside it and the bloodwork that tests it.